RIF — Competitive Intelligence Brief

RIF (RIF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Oncology (supportive care) / Infectious Disease.

marketed Rifamycin antibiotic Bacterial RNA polymerase Oncology (supportive care) / Infectious Disease Small molecule

Target snapshot

RIF (RIF) — South China Children's Leukemia Group. RIF is a rifampicin-based antimicrobial agent used in pediatric leukemia supportive care to prevent or treat infections.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RIF TARGET	RIF	South China Children's Leukemia Group	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
PB 6 doses - Rifampicin and Dapsone	PB 6 doses - Rifampicin and Dapsone	University of Brasilia	marketed	Antileprosy combination therapy	Bacterial RNA polymerase (rifampicin); dihydropteroate synthase (dapsone)
Rifampicin (R)	Rifampicin (R)	University College, London	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
HR	HR	Global Alliance for TB Drug Development	marketed	Anti-tuberculosis agent (fixed-dose combination)	Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)
clarithromycin, rifabutin	clarithromycin, rifabutin	The University of Texas Health Science Center at Tyler	marketed	Macrolide antibiotic and rifamycin antibiotic combination	Bacterial 50S ribosomal subunit (clarithromycin); bacterial RNA polymerase (rifabutin)
Rifampicin alone	Rifampicin alone	Miguel Santín	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifamycin-containing regimen	Rifamycin-containing regimen	National Taiwan University Hospital	marketed	Rifamycin antibiotic	Bacterial RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class